Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio

British Journal of Clinical Pharmacology

Volumn 42, Issue 3, 1996, Pages 333-337

  De Pinieux, G ^a   Chariot, P ^a   Ammi SaiD M ^a   Louarn, F ^b   Lejonc, J L ^a   Astier, A ^a   Jacotot, B ^a   Gherardi, R ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b Hopital Albert Chenevier   (France)

Author keywords

Fibrates; Hypercholesterolaemia; Lactate; Mitochondria; Statins; Ubiquinone

Indexed keywords

ANTILIPEMIC AGENT; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; MEVALONIC ACID; PRAVASTATIN; PYRUVIC ACID; SIMVASTATIN; UBIQUINONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; PRIORITY JOURNAL;

EID: 0029837064     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.04178.x     Document Type: Article

References (35)

1. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolaemia. N Engl J Med 1988; 319: 24-33.
2. Stalenhoef AFH, Mol MJT, Stuyt PMJ. Efficacy and tolerability of simvastatin. Am J Med 1989; 87 (4A): 39S-43S.
3. London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy. Neurology 1991; 41: 1159-1160.
4. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin. Ann Intern Med 1991; 114: 342.
5. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992; 327: 649-650.
6. Contermans J, Smit JWA, Bär PR, Erkelens DW. A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients. Br J Clin Pharmacol 1995; 39: 135-141.
7. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131: 163-174.
8. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-75.
9. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes and myopathy. Lancet 1989; ii: 1097.
10. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi R. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993; 94: 109-110.
11. Bardosi A, Scheidt P, Goebel HH. 1985. Mitochondrial myopathy. A result of Clofibrate/Etofibrate treatment. Acta Neuropathol 1985; 68: 164-168.
12. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in human. Proc Natl Acad Sci USA, 1990; 87: 8931-8934.
13. Elmberger PG, Kalén A, Lund E, et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolaemia. J Lipid Res 1991; 32: 935-940.
14. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33: 226-229.
15. Watts GF, Castellucio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46: 1055-1057.
16. Mitchell P. 1991. The vital protonmotive role of coenzyme Q. In Biomedical and clinical aspects of coenzyme Q, eds. Littarru GP, Yamagami T, Folkers K, Elsevier, Amsterdam, 1991: 3-10.
17. Robinson BH. Lactic acidemia. In The metabolic basis of inherited disease. 6th ed., eds. Scriver CR, Beaudet AL, Sly WS, Valle D, McGraw Hill, New York, 1989: 869-888.
18. Munnich A, Rustin P, Rötig A, et al. Clinical aspects of mitochondrial disorders. J Inher Metab Dis 1992; 15: 448-455.
19. Chariot P, Ratiney R, Ammi Said M, Hérigault R, Adnot S, Gherardi R. Optimal handling of blood samples for routine measurement of lactate and pyruvate. Arch Pathol Lab Med 1994; 118: 695-697.
20. Chariot P, Monnet I, Mouchet M, et al. Determination of the blood lactate: pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum 1994; 37: 583-586.
21. Vassault A, Bonnefont JP, Specola N, Saudubray JM. Lactate, pyruvate, and ketone bodies. In Techniques in diagnostic human biochemical genetics: a laboratory manual, ed. Homme P, Wiley-Liss, New-York. 1991: 285-308.
22. Okamoto T, Fukui K Nakamoto M, Kishi T. High-performance liquid chromatography of coenzyme Q-related compounds and its application to biological materials. J Chromatogr 1985; 342: 35-46.
23. Okamoto T, Fukunaga Y, Ida Y, Kishi T. Determination of reduced and total ubiquinones in biological materials by liquid chromatography with electrochemical detection. J Chromatogr 1988; 430: 11-19.
24. Warnick GR, Cheung MC, Albers JJ. Comparison of current methods for high-density lipoprotein cholesterol quantitation. Clin Chem 1979; 25: 596-604.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
26. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short-and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46: 313-317.
27. Munnich A, Saudubray JM. Les cytopathies mitochondriales. Arch Fr Pediatr 1991; 48: 163-166.
28. Smith PF, R.S. Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas, KP, Kari PH, MacDonald JS. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225-1235.
29. Waclawik AJ, Lindal S, Engel AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993; 52: 542-549.
30. Nakahara K, Kuriyama M, Yoshidome H, et al. Experimental simvastatin-induced myopathy in rabbits, J Neurol Sci 1992; 113: 114-117.
31. Abourizk N, Khalil BA, Bahuth N, Afifi AKK. Clofibrate-induced muscular syndrome. J Neurol Sci 1979; 42: 1-9.
32. Low P, Andersson M, Edlund C, Dallner G. Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta 1991; 1165: 102-109.
33. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalo-myopathy. Proc Natl Acad Sci USA 1989; 86: 2379-2382.
34. Maltese WA, Aprille JR. Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells. J Biol Chem 1985; 260: 11524-11529.
35. Matthews PM, Ford B, Dandurand RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993; 43: 884-890.